JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)

Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at HC Wainwright from $210.00 to $204.00.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at BMO Capital Markets from $185.00 to $188.00. They now have an "outperform" rating on the stock.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at SVB Leerink LLC from $200.00 to $210.00. They now have an "outperform" rating on the stock.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at UBS Group AG from $194.00 to $191.00. They now have a "buy" rating on the stock.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at Morgan Stanley.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at UBS Group AG.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at SVB Leerink LLC.

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

Avadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rival [Seeking Alpha]

Jazz Pharmaceuticals Is Trading on an Up Note [TheStreet.com]

Axsome: One Step At A Time [Seeking Alpha]

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

Redx to Get $5 Mln on Tumor Drug Milestone With US Regulator [MarketWatch]

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting